|drug2804||Recombinant Interferon Alfa-2b Wiki||1.00|
|drug3071||Serology SARS-CoV2 Wiki||1.00|
|drug991||Data collection Wiki||0.45|
|D003141||Communicable Diseases NIH||0.07|
There is one clinical trial.
This prospective phase I/IIa trial studies the side effects of rintatolimod and Intron A (IFNa) alpha-2b in treating cancer patients with mild or moderate COVID-19 infection. Interferon alpha is a protein important for defense against viruses. It activates immune responses that help to clear viral infection. Rintatolimod is double stranded ribonucleic acid (RNA) designed to mimic viral infection by stimulating immune pathways that are normally activated during viral infection. Giving rintatolimod and interferon alpha-2b may activate the immune system to limit the replication and spread of the virus.
Description: This refers to the frequency of grade 3 or 4 AEs considered to be possibly, probably or definitely related to the treatment regimen. Toxicity will be assessed according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events Version 5.0 (CTCAE version [v] 5.0).Measure: Incidence of adverse events (AEs) Time: Up to 30 days post treatment intiation
Description: will be evaluated based on quantitative polymerase chain reaction PCRMeasure: Kinetics of viral load in nasopharyngeal swabs Time: Up to 30 days post treatment initiation
Description: Will be analyzed using quantitative polymerase chain reaction (PCR).Measure: Kinetics of viral load in the peripheral blood and nasopharyngeal swabs Time: During the course of treatment up to day 30
Description: The circulatory inflammatory mediators include C-reactive protein (CRP), cytokines, chemokines, interferons.Measure: Kinetics of changes of the immune subsets and circulating inflammatory mediators in peripheral blood Time: During the course of treatment up to day 30
Description: The binary endpoint of 30-day mortality will be analyzed using a logistic regression model.Measure: 30-day mortality Time: At 30 days post treatment initiation
Description: Rate of hospitalization due to infectionMeasure: Hospitalization due to infection Time: Up to 30 days post treatment initiation
Description: Will be tested in nasopharyngeal swabs and blood cells of patientsMeasure: Determine known mediators of antiviral immunity Time: UP to 30 days post treatment initiation
Description: ARDS will be defined by Berlin criteriaMeasure: acute respiratory distress syndrome (ARDS) Time: Up to 30 days post treatment initiation
Description: Need for mechanical ventilationMeasure: respiratory failure requiring mechanical ventilation Time: up to 30 days post treatment initiation
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports